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Reply to Stephan et al.
To the Editor: Stephan et al. advocate for a responsible
approach to the use of personal genomic proﬁles in disease
prevention, early detection, and treatment. They stress
that companies should use only results of high-quality
association studies to bring customers accurate genetic
risk predictions, as well as effective strategies for reducing
risk for those conditions to which they are predisposed.
We agree fully.
Our review of genomic proﬁles currently offered by
seven different companies found that all of the proﬁles
were based in part on genetic associations that are not
well established.1 On average, statistically signiﬁcant asso-
ciations were found for 58% of the genes included in the
proﬁles listed in Table 1 of our article, which speciﬁes the
results per company. This percentage varied among proﬁles
offered by each company: 38% to 83% for the proﬁles of-
fered by Company 1, 38% to 60% for Company 2, and
40% to 80% for Company 3. Companies 4, 5, 6, and 7
each offered a single proﬁle; for these proﬁles, the propor-
tions of included gene variants with statistically signiﬁcant
associations were 42%, 80%, 47%, and 47%, respectively.
All of these proportions can be calculated directly from
Table 1 in our article.1
Stephan et al. note that genome-wide association stud-
ies have provided strong evidence for disease associations
with several genes in multiple studies, including TCF7L2
(MIM 602228) and NOD2 (MIM 605956), and that
customers can beneﬁt from a personalized report of these
associations. On the whole, our review found that even
statistically signiﬁcant associations had fairly small
effects on disease risk. The associations with the largest
effects were of APOE (MIM 107740) and IL-6 (MIM
147620) with Alzheimer’s disease (MIM 104300) (odds
ratios [ORs] 3.2 and 0.54, respectively) and TNF-a (MIM
191160) with systemic lupus erythematosus (MIM
152700) (OR 2.1) and psoriasis (MIM 177900) (OR 0.57).
These effects are larger than the effect of TCF7L2 on the
risk of type 2 diabetes (MIM 125853)2 and are comparable
to the per-allele effect of NOD2 on the risk of Crohn’s
disease (MIM 266600) in most populations.3 Most
genetic variants identiﬁed in genome-wide association
studies have even smaller effects in the range of OR
1.15–1.35.
Although establishing robust, consistent genetic associ-
ations is a necessary ﬁrst step to developing any genetic
test, robust association is insufﬁcient to establish utility.
Genetic variants with small effects—and even genetic
variants with apparently large effects—tend to have low
predictive value, because the difference in absolute risks
between carriers and noncarriers of the risk variants tends
to be small.4,5 Determining whether combining tests for
multiple variants in genomic proﬁles will yield higher pre-Thdictive value still requires empirical evidence. Further-
more, evidence is lacking to argue that knowledge of risk
is sufﬁcient to motivate healthy behavior in carriers with-
out promoting complacency in noncarriers. Controlled
clinical trials are needed to assess the impact of such infor-
mation on behavior change in people with positive and
negative tests.
At this stage, given our incomplete knowledge in the
genetics of common diseases, there is no evidence that
health beneﬁts can be meaningfully personalized on the
basis of genomic proﬁles. Therefore, a responsible ap-
proach to personal genomics requires conducting addi-
tional research to adequately translate genomic research
ﬁndings into useful tools for disease prevention. At the
same time, it is important to continue to educate the pub-
lic that healthy behavior—such as physical activity and
eating a balanced diet—is good for all, regardless of genetic
susceptibility.
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Web Resources
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim/
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